Allergan plc (NYSE: AGN) today announced the company has received approval from the U.S. Food and Drug Administration (FDA) to market NATRELLE INSPIRA® Cohesive breast implants, offering women undergoing reconstruction, augmentation or revision surgery a new breast shaping option that combines a high gel fill ratio and Allergan's highly cohesive gel for a customized result. The new NATRELLE INSPIRA® Cohesive line of breast implants is the newest entry into the category of breast implants commonly referred to as "gummy" implants, designed for women who are interested in increased breast fullness.
"NATRELLE INSPIRA® Cohesive breast implants are just the latest example of our commitment to innovation in breast aesthetics and plastic surgery, and we are proud that we are able to continue to offer advancements in technology that allow physicians and their patients more options," said David Nicholson, Chief R&D Officer of Allergan plc. "NATRELLE INSPIRA® Cohesive allows patients to get the same high gel fill ratio and fullness offered by the NATRELLE INSPIRA® line of implants, with our highly cohesive, form-stable gel.
The FDA approval of NATRELLE INSPIRA® Cohesive breast implants, which are available with both smooth and BIOCELL® textured surfaces, marks the most recent addition to the broad portfolio of currently available NATRELLE® products in the US. The smooth version of the NATRELLE INSPIRA® round gel-filled breast implants with responsive gel was approved by FDA in February 2015, and the textured version of the NATRELLE INSPIRA® round gel-filled breast implants with responsive gel were approved by the FDA in June 2015.
"I make it my personal mission to give my patients the best possible cosmetic results after breast reconstruction," said Dr. Lisa Cassileth of Cassileth Plastic Surgery. "I've been waiting for a form stable, cohesive round implant. I've been waiting for NATRELLE INSPIRA® Cohesive"
Ultra-processed foods raise chronic kidney disease risk, study shows